TP53 and neoplasm: AURKA is a viable target in cancer therapy, since its overexpression is common in tumours [290,291], and it has been reported in upper gastrointestinal adenocarcinomas, with the AURKA/AKT axis being an important pathway for enhancing the antiapoptotic characteristics of cancer cells through the regulation of p53-dependent apoptosis [290].